colchicine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
726 64-86-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • colchicine
  • colchisol
  • colcin
A major alkaloid from Colchicum autumnale L. and found also in other Colchicum species. Its primary therapeutic use is in the treatment of gout, but it has been used also in the therapy of familial Mediterranean fever (PERIODIC DISEASE). Potential to limit COVID-19-related myocardial damage has been hypothesized based on the drug’s mechanisms of action and promising results of ongoing research on colchicine in various cardiac conditions. However, the drug's safety and efficacy for treatment of COVID-19 is not yet established.
  • Molecular weight: 399.44
  • Formula: C22H25NO6
  • CLOGP: 1.29
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 83.09
  • ALOGS: -4.16
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1 mg O
1 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.29 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Hosey CM, Chan R, Benet LZ
S (Water solubility) 10 mg/mL Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 6.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.61 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 58 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 27, 1961 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gout 292.45 13.19 141 32662 13130 63443089
Enthesopathy 266.86 13.19 116 32687 8498 63447721
Panniculitis 241.93 13.19 118 32685 11267 63444952
Tenosynovitis 231.82 13.19 122 32681 13673 63442546
Tongue disorder 219.85 13.19 108 32695 10472 63445747
Blood parathyroid hormone decreased 218.66 13.19 105 32698 9686 63446533
Red blood cell sedimentation rate 203.08 13.19 81 32722 4773 63451446
Skin necrosis 194.43 13.19 109 32694 13841 63442378
Granuloma skin 193.03 13.19 92 32711 8345 63447874
Tendonitis 179.52 13.19 117 32686 19498 63436721
Rheumatoid nodule 171.03 13.19 108 32695 17047 63439172
Ulcer 151.58 13.19 118 32685 25989 63430230
Hypercalcaemia 138.95 13.19 116 32687 28206 63428013
Drug eruption 135.57 13.19 115 32688 28579 63427640
Basal cell carcinoma 125.76 13.19 109 32694 27882 63428337
Loss of employment 124.50 13.19 46 32757 2198 63454021
Alanine aminotransferase abnormal 115.03 13.19 53 32750 4451 63451768
Toxicity to various agents 113.47 13.19 332 32471 246918 63209301
Skin ulcer 113.20 13.19 125 32678 42920 63413299
Fear of injection 97.17 13.19 55 32748 7109 63449110
C-reactive protein abnormal 94.79 13.19 118 32685 45978 63410241
Aspartate aminotransferase increased 85.30 13.19 161 32642 90116 63366103
Red blood cell sedimentation rate increased 84.74 13.19 109 32694 43873 63412346
Rash pruritic 82.15 13.19 126 32677 59673 63396546
Glossodynia 79.26 13.19 3 32800 178873 63277346
Gastric disorder 78.98 13.19 97 32706 37272 63418947
Acute kidney injury 78.46 13.19 306 32497 263109 63193110
Alanine aminotransferase increased 73.16 13.19 164 32639 103606 63352613
Diarrhoea 72.34 13.19 622 32181 714744 62741475
Drug reaction with eosinophilia and systemic symptoms 70.17 13.19 87 32716 33749 63422470
Urticarial vasculitis 69.41 13.19 22 32781 657 63455562
Inflammation 67.15 13.19 138 32665 82135 63374084
Drug tolerance decreased 64.61 13.19 61 32742 17412 63438807
Hand deformity 63.47 13.19 5 32798 159452 63296767
Drug interaction 62.46 13.19 259 32544 228872 63227347
C-reactive protein increased 60.50 13.19 144 32659 94563 63361656
Granuloma 59.24 13.19 37 32766 5724 63450495
Psoriatic arthropathy 55.08 13.19 136 32667 91384 63364835
Defaecation disorder 54.60 13.19 19 32784 762 63455457
Maternal exposure during pregnancy 52.49 13.19 24 32779 220038 63236181
Hypersensitivity vasculitis 51.57 13.19 30 32773 4082 63452137
Rheumatoid lung 50.72 13.19 29 32774 3819 63452400
Drug tolerance 50.60 13.19 36 32767 6913 63449306
Echocardiogram abnormal 50.50 13.19 21 32782 1377 63454842
Gouty tophus 47.34 13.19 13 32790 232 63455987
Blood pressure systolic increased 46.57 13.19 86 32717 47311 63408908
Drug resistance 46.00 13.19 58 32745 22875 63433344
Joint injury 44.43 13.19 65 32738 29507 63426712
Drug hypersensitivity 41.12 13.19 288 32515 310399 63145820
Rhabdomyolysis 38.56 13.19 76 32727 43875 63412344
Multiple organ dysfunction syndrome 38.09 13.19 88 32715 56664 63399555
Erythema 37.59 13.19 185 32618 175566 63280653
Myopathy 37.48 13.19 37 32766 11154 63445065
Off label use 37.07 13.19 520 32283 673942 62782277
Loss of personal independence in daily activities 36.52 13.19 122 32681 97168 63359051
Hepatic steatosis 34.51 13.19 57 32746 28712 63427507
Neuromyopathy 34.32 13.19 13 32790 666 63455553
Pericardial effusion 33.98 13.19 58 32745 30000 63426219
Drug intolerance 32.89 13.19 272 32531 308389 63147830
Episcleritis 32.71 13.19 14 32789 986 63455233
Chronic kidney disease 32.24 13.19 72 32731 45326 63410893
Irritable bowel syndrome 31.65 13.19 3 32800 82409 63373810
Malignant neoplasm progression 31.51 13.19 3 32800 82118 63374101
Faeces soft 31.45 13.19 25 32778 5667 63450552
Drug ineffective for unapproved indication 31.22 13.19 60 32743 34003 63422216
Enterococcal sepsis 31.02 13.19 15 32788 1403 63454816
Familial mediterranean fever 30.52 13.19 7 32796 57 63456162
Therapy non-responder 30.11 13.19 97 32706 75804 63380415
Swelling 29.72 13.19 61 32742 275317 63180902
Metabolic acidosis 29.27 13.19 69 32734 45000 63411219
Appetite disorder 27.91 13.19 26 32777 7295 63448924
Acute febrile neutrophilic dermatosis 27.84 13.19 18 32785 2956 63453263
Musculoskeletal disorder 27.63 13.19 43 32760 20601 63435618
Pancytopenia 27.48 13.19 111 32692 96822 63359397
Conjunctival haemorrhage 27.08 13.19 19 32784 3568 63452651
Lower respiratory tract infection 26.38 13.19 18 32785 132289 63323930
Systemic lupus erythematosus 26.36 13.19 42 32761 208876 63247343
Impaired healing 26.34 13.19 10 32793 102532 63353687
Disseminated intravascular coagulation 25.94 13.19 40 32763 19011 63437208
Iodine allergy 25.46 13.19 11 32792 793 63455426
Overdose 25.21 13.19 122 32681 114956 63341263
Seizure 25.19 13.19 19 32784 132615 63323604
Blood creatine phosphokinase increased 24.76 13.19 51 32752 30379 63425840
Rheumatoid arthritis 24.56 13.19 219 32584 253600 63202619
Blood cholesterol increased 24.43 13.19 9 32794 94023 63362196
Therapeutic response decreased 23.84 13.19 78 32725 61447 63394772
Neutrophilic dermatosis 23.19 13.19 7 32796 177 63456042
Allergy to metals 23.09 13.19 10 32793 725 63455494
Blood creatine phosphokinase decreased 22.66 13.19 9 32794 524 63455695
Febrile neutropenia 22.45 13.19 17 32786 118432 63337787
Memory impairment 22.41 13.19 13 32790 104245 63351974
Cardiac tamponade 22.26 13.19 19 32784 4756 63451463
Gouty arthritis 21.91 13.19 9 32794 572 63455647
Cardiac failure congestive 21.70 13.19 100 32703 92333 63363886
Osteomyelitis 21.63 13.19 44 32759 25976 63430243
Parotid gland enlargement 21.61 13.19 10 32793 848 63455371
Pharyngitis streptococcal 21.41 13.19 27 32776 10645 63445574
Arthritis 21.29 13.19 117 32686 115804 63340415
Skin disorder 21.18 13.19 47 32756 29460 63426759
Anxiety 21.15 13.19 51 32752 217490 63238729
Blood creatinine increased 20.60 13.19 95 32708 87749 63368470
Drug abuse 20.49 13.19 6 32797 72512 63383707
Arthralgia 20.42 13.19 410 32393 569300 62886919
Product use issue 20.17 13.19 188 32615 220332 63235887
International normalised ratio increased 19.94 13.19 61 32742 46364 63409855
Ileal ulcer 19.91 13.19 8 32795 480 63455739
Cardiac failure 19.87 13.19 95 32708 89047 63367172
Sinusitis 19.85 13.19 56 32747 226597 63229622
Amegakaryocytic thrombocytopenia 19.85 13.19 4 32799 16 63456203
Natural killer cell count 19.85 13.19 4 32799 16 63456203
Heart rate abnormal 19.69 13.19 18 32785 4929 63451290
Confusional state 19.55 13.19 60 32743 236320 63219899
Injection site oedema 19.43 13.19 11 32792 1421 63454798
Ill-defined disorder 19.34 13.19 9 32794 81746 63374473
Behcet's syndrome 19.34 13.19 5 32798 70 63456149
Bone marrow failure 19.19 13.19 45 32758 29245 63426974
Leukopenia 19.18 13.19 85 32718 77205 63379014
Dizziness 19.03 13.19 137 32666 429788 63026431
Musculoskeletal stiffness 18.73 13.19 161 32642 184457 63271762
HCoV-HKU1 infection 18.65 13.19 4 32799 23 63456196
Macrophages increased 18.65 13.19 4 32799 23 63456196
Knee arthroplasty 18.32 13.19 3 32800 54203 63402016
Discomfort 18.10 13.19 37 32766 167337 63288882
Lymphadenopathy 17.91 13.19 52 32751 38406 63417813
Hepatocellular injury 17.86 13.19 42 32761 27339 63428880
Asthma 17.69 13.19 24 32779 127537 63328682
Eye symptom 17.58 13.19 5 32798 102 63456117
White blood cell count decreased 17.51 13.19 28 32775 139076 63317143
Muscle injury 17.41 13.19 6 32797 65339 63390880
Pneumonia 17.24 13.19 152 32651 456615 62999604
Blood pressure systolic decreased 16.93 13.19 20 32783 7377 63448842
Acarodermatitis 16.56 13.19 9 32794 1074 63455145
Hypergammaglobulinaemia benign monoclonal 16.47 13.19 8 32795 756 63455463
Tendinous contracture 16.40 13.19 5 32798 131 63456088
Eye haemorrhage 16.27 13.19 21 32782 8475 63447744
Hyperaesthesia 16.17 13.19 22 32781 9336 63446883
Suicidal ideation 16.17 13.19 6 32797 62415 63393804
Hypertriglyceridaemia 16.14 13.19 18 32785 6241 63449978
Wound 16.08 13.19 38 32765 163225 63292994
Acute abdomen 15.91 13.19 10 32793 1563 63454656
Accidental exposure to product by child 15.75 13.19 9 32794 1184 63455035
Chondrocalcinosis pyrophosphate 15.71 13.19 9 32794 1189 63455030
Cutaneous tuberculosis 15.66 13.19 5 32798 153 63456066
Hepatosplenomegaly 15.57 13.19 12 32791 2602 63453617
Meningocele 15.55 13.19 3 32800 9 63456210
Vasculitis 15.38 13.19 31 32772 18178 63438041
Hepatic cytolysis 15.18 13.19 28 32775 15379 63440840
Nausea 15.11 13.19 561 32242 853910 62602309
Angiopathy 14.98 13.19 15 32788 4598 63451621
Symptom recurrence 14.63 13.19 10 32793 1800 63454419
Injury 14.55 13.19 10 32793 73237 63382982
Toxic epidermal necrolysis 14.55 13.19 37 32766 25297 63430922
Myocarditis 14.51 13.19 22 32781 10303 63445916
Skin irritation 14.04 13.19 21 32782 9720 63446499
Vascular purpura 13.97 13.19 9 32794 1469 63454750
Rash maculo-papular 13.78 13.19 42 32761 31854 63424365
Multiple sclerosis relapse 13.72 13.19 4 32799 48474 63407745
Neutrophilia 13.71 13.19 14 32789 4392 63451827
Pain 13.53 13.19 286 32517 740342 62715877
Vaccination failure 13.42 13.19 7 32796 769 63455450
Disease progression 13.39 13.19 27 32776 122731 63333488
Sexual inhibition 13.36 13.19 3 32800 22 63456197

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gout 386.90 12.05 235 32535 19018 34905143
Rhabdomyolysis 198.31 12.05 280 32490 67883 34856278
Myopathy 177.22 12.05 119 32651 11435 34912726
Tenosynovitis 164.43 12.05 82 32688 4488 34919673
Enthesopathy 160.76 12.05 81 32689 4532 34919629
Drug interaction 144.29 12.05 502 32268 225444 34698717
Neuromyopathy 136.42 12.05 47 32723 987 34923174
Tongue disorder 135.83 12.05 76 32694 5263 34918898
Toxicity to various agents 125.08 12.05 442 32328 199920 34724241
Acute kidney injury 120.39 12.05 584 32186 304404 34619757
Pericarditis 102.51 12.05 86 32684 11559 34912602
C-reactive protein abnormal 101.78 12.05 76 32694 8634 34915527
Diarrhoea 101.72 12.05 668 32102 389244 34534917
Alanine aminotransferase abnormal 90.95 12.05 56 32714 4632 34919529
Synovitis 88.53 12.05 86 32684 13980 34910181
Drug reaction with eosinophilia and systemic symptoms 87.68 12.05 130 32640 32882 34891279
Tendonitis 85.66 12.05 70 32700 9070 34915091
Drug abuse 70.57 12.05 6 32764 99090 34825071
Myopathy toxic 59.74 12.05 22 32748 564 34923597
Red blood cell sedimentation rate 50.81 12.05 24 32746 1164 34922997
Granuloma skin 49.13 12.05 24 32746 1255 34922906
Aspartate aminotransferase increased 46.89 12.05 155 32615 67628 34856533
Treatment failure 45.89 12.05 121 32649 46576 34877585
Panniculitis 44.33 12.05 26 32744 1968 34922193
Therapeutic response decreased 43.13 12.05 89 32681 29224 34894937
Blood parathyroid hormone decreased 42.98 12.05 23 32747 1457 34922704
Multiple organ dysfunction syndrome 39.35 12.05 159 32611 76407 34847754
Loss of personal independence in daily activities 38.93 12.05 92 32678 33087 34891074
Overdose 36.12 12.05 175 32595 90884 34833277
Serum amyloid A protein increased 35.88 12.05 9 32761 57 34924104
Death 35.69 12.05 223 32547 397826 34526335
Gouty arthritis 34.73 12.05 18 32752 1068 34923093
Malignant neoplasm progression 34.25 12.05 20 32750 88026 34836135
Familial mediterranean fever 33.33 12.05 8 32762 41 34924120
Alanine aminotransferase increased 33.26 12.05 157 32613 80658 34843503
Ulcer 32.88 12.05 41 32729 8794 34915367
Gouty tophus 32.34 12.05 10 32760 147 34924014
Drug intolerance 31.64 12.05 125 32645 59445 34864716
Rheumatoid nodule 30.65 12.05 24 32746 2923 34921238
Blood uric acid increased 30.11 12.05 41 32729 9583 34914578
Spermatozoa progressive motility decreased 29.44 12.05 9 32761 127 34924034
Erythema 28.55 12.05 161 32609 88619 34835542
Pericardial effusion 28.51 12.05 68 32702 24594 34899567
Renal failure 27.54 12.05 213 32557 130344 34793817
Myalgia 26.70 12.05 152 32618 83958 34840203
Psoriatic arthropathy 26.67 12.05 58 32712 19740 34904421
Musculoskeletal toxicity 24.96 12.05 8 32762 133 34924028
Pleuropericarditis 24.76 12.05 9 32761 222 34923939
Hypertrophic osteoarthropathy 24.41 12.05 7 32763 78 34924083
Herbal interaction 23.73 12.05 10 32760 369 34923792
Agranulocytosis 23.67 12.05 62 32708 23759 34900402
Drug hypersensitivity 23.28 12.05 142 32628 80387 34843774
Metabolic acidosis 22.66 12.05 91 32679 43589 34880572
Contraindicated product administered 22.47 12.05 57 32713 21424 34902737
Seizure 22.38 12.05 40 32730 104817 34819344
Shock 22.08 12.05 61 32709 24118 34900043
Myocarditis 21.86 12.05 43 32727 13639 34910522
Myositis 21.84 12.05 40 32730 12030 34912131
Aggression 21.60 12.05 5 32765 38959 34885202
Disease progression 21.52 12.05 43 32727 108034 34816127
Completed suicide 21.15 12.05 161 32609 98007 34826154
Cardiac vein perforation 20.93 12.05 5 32765 25 34924136
Heart sounds abnormal 20.83 12.05 12 32758 878 34923283
Leukocytosis 20.30 12.05 59 32711 24006 34900155
Skin necrosis 19.94 12.05 26 32744 5827 34918334
Cholestasis 19.86 12.05 63 32707 26885 34897276
Febrile neutropenia 19.85 12.05 64 32706 136785 34787376
Insulin autoimmune syndrome 19.17 12.05 8 32762 288 34923873
Somnolence 19.02 12.05 48 32722 111068 34813093
Scrotal erythema 18.30 12.05 5 32765 46 34924115
Biopsy muscle abnormal 17.92 12.05 3 32767 0 34924161
Meningitis gonococcal 17.92 12.05 3 32767 0 34924161
Thrombocytopenic purpura 17.74 12.05 12 32758 1165 34922996
Cardiogenic shock 17.61 12.05 60 32710 26558 34897603
Bradycardia foetal 17.58 12.05 8 32762 356 34923805
Cellulitis 16.34 12.05 95 32675 52856 34871305
Mixed dementia 16.30 12.05 7 32763 271 34923890
Blood creatine phosphokinase increased 16.20 12.05 84 32686 44773 34879388
Sinus arrhythmia 16.16 12.05 10 32760 834 34923327
Stomatitis 16.04 12.05 10 32760 42504 34881657
Cardiac tamponade 15.82 12.05 22 32748 5244 34918917
Foetal exposure during pregnancy 15.76 12.05 8 32762 38093 34886068
Pneumonia 15.51 12.05 243 32527 362384 34561777
Necrotising myositis 15.41 12.05 9 32761 676 34923485
Arthritis 15.22 12.05 64 32706 31282 34892879
Rheumatoid lung 15.15 12.05 10 32760 932 34923229
Renal vasculitis 15.04 12.05 6 32764 192 34923969
Hepatitis acute 14.79 12.05 26 32744 7575 34916586
Fear of injection 14.78 12.05 12 32758 1540 34922621
Hepatic cytolysis 14.67 12.05 38 32732 14458 34909703
Suicidal ideation 14.56 12.05 10 32760 40378 34883783
Intentional overdose 14.56 12.05 80 32690 43594 34880567
Pulmonary embolism 14.42 12.05 40 32730 89706 34834455
Hepatosplenomegaly neonatal 14.34 12.05 4 32766 40 34924121
Arthralgia 14.18 12.05 231 32539 169810 34754351
Chronic kidney disease 14.08 12.05 76 32694 41134 34883027
Hepatic enzyme increased 13.99 12.05 73 32697 39007 34885154
Mouth ulceration 13.94 12.05 33 32737 11877 34912284
Rash pruritic 13.86 12.05 56 32714 26885 34897276
Bursitis 13.77 12.05 21 32749 5437 34918724
Hypocalcaemia 13.73 12.05 52 32718 24237 34899924
Skin hyperpigmentation 13.53 12.05 16 32754 3248 34920913
Mixed liver injury 13.46 12.05 15 32755 2858 34921303
Scleroderma renal crisis 13.44 12.05 6 32764 255 34923906
Penile discomfort 13.31 12.05 3 32767 11 34924150
Gastrointestinal disorder 13.26 12.05 65 32705 33883 34890278
Vasoplegia syndrome 12.92 12.05 12 32758 1844 34922317
Platelet count decreased 12.89 12.05 63 32707 119654 34804507
Sperm concentration decreased 12.81 12.05 5 32765 151 34924010
Confusional state 12.73 12.05 81 32689 144079 34780082
Pericardial haemorrhage 12.30 12.05 15 32755 3143 34921018
Spider vein 12.20 12.05 5 32765 172 34923989
Angioedema 12.15 12.05 68 32702 37306 34886855

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Gout 531.03 11.54 287 56717 24462 79662922
Enthesopathy 376.26 11.54 178 56826 11430 79675954
Tenosynovitis 346.56 11.54 185 56819 15369 79672015
Tongue disorder 310.73 11.54 166 56838 13809 79673575
Rhabdomyolysis 252.56 11.54 339 56665 102792 79584592
Tendonitis 240.64 11.54 171 56833 23659 79663725
Toxicity to various agents 232.43 11.54 745 56259 420795 79266589
Myopathy 217.95 11.54 152 56852 20411 79666973
Drug interaction 212.90 11.54 716 56288 414467 79272917
Panniculitis 212.40 11.54 124 56880 12247 79675137
Alanine aminotransferase abnormal 207.51 11.54 109 56895 8758 79678626
Blood parathyroid hormone decreased 206.10 11.54 115 56889 10421 79676963
Acute kidney injury 205.19 11.54 823 56181 518581 79168803
Red blood cell sedimentation rate 204.17 11.54 93 56911 5472 79681912
Granuloma skin 187.31 11.54 103 56901 9071 79678313
Neuromyopathy 172.40 11.54 58 56946 1500 79685884
Skin necrosis 164.87 11.54 122 56882 17965 79669419
Rheumatoid nodule 159.80 11.54 118 56886 17320 79670064
Drug reaction with eosinophilia and systemic symptoms 158.44 11.54 212 56792 64032 79623352
Diarrhoea 154.68 11.54 1116 55888 879373 78808011
C-reactive protein abnormal 145.17 11.54 176 56828 48191 79639193
Ulcer 135.04 11.54 135 56869 29837 79657547
Aspartate aminotransferase increased 108.13 11.54 278 56726 138363 79549021
Fear of injection 105.29 11.54 66 56938 7408 79679976
Hypercalcaemia 101.20 11.54 131 56873 38299 79649085
Basal cell carcinoma 100.92 11.54 129 56875 37246 79650138
Loss of employment 100.50 11.54 45 56959 2542 79684842
Drug eruption 96.30 11.54 137 56867 43798 79643586
Skin ulcer 90.65 11.54 149 56855 54001 79633383
Alanine aminotransferase increased 87.13 11.54 285 56719 162285 79525099
Multiple organ dysfunction syndrome 85.50 11.54 233 56771 120013 79567371
Rash pruritic 79.39 11.54 165 56839 71464 79615920
Drug abuse 77.14 11.54 12 56992 162679 79524705
Gouty tophus 76.40 11.54 23 56981 410 79686974
Gastric disorder 73.74 11.54 111 56893 37322 79650062
Psoriatic arthropathy 69.88 11.54 165 56839 77834 79609550
Myopathy toxic 65.80 11.54 26 56978 1072 79686312
Overdose 65.40 11.54 283 56721 183923 79503461
Loss of personal independence in daily activities 61.51 11.54 187 56817 102393 79584991
Glossodynia 61.30 11.54 3 57001 103334 79584050
Rheumatoid lung 61.09 11.54 38 56966 4207 79683177
Familial mediterranean fever 60.70 11.54 16 56988 171 79687213
Erythema 58.97 11.54 315 56689 222975 79464409
Drug tolerance decreased 57.61 11.54 58 56946 12920 79674464
Granuloma 56.23 11.54 47 56957 8250 79679134
Red blood cell sedimentation rate increased 55.86 11.54 110 56894 45832 79641552
Hand deformity 55.84 11.54 5 56999 103914 79583470
Maternal exposure during pregnancy 54.57 11.54 15 56989 136523 79550861
Pericardial effusion 52.98 11.54 108 56896 46129 79641255
Drug tolerance 52.40 11.54 46 56958 8629 79678755
C-reactive protein increased 50.28 11.54 204 56800 128823 79558561
Metabolic acidosis 49.98 11.54 151 56853 82378 79605006
Therapeutic response decreased 49.96 11.54 132 56872 66721 79620663
Gouty arthritis 49.17 11.54 23 56981 1438 79685946
Treatment failure 48.79 11.54 246 56758 170240 79517144
Therapy non-responder 48.68 11.54 161 56843 92144 79595240
Malignant neoplasm progression 45.64 11.54 20 56984 135970 79551414
Defaecation disorder 43.41 11.54 17 56987 684 79686700
Inflammation 42.89 11.54 156 56848 93597 79593787
Blood creatine phosphokinase increased 41.99 11.54 123 56881 65967 79621417
Chronic kidney disease 40.96 11.54 122 56882 66032 79621352
Joint injury 40.50 11.54 77 56927 31258 79656126
Drug intolerance 40.48 11.54 325 56679 263794 79423590
Cardiac tamponade 40.34 11.54 41 56963 9235 79678149
Drug ineffective for unapproved indication 39.13 11.54 102 56902 51136 79636248
Drug hypersensitivity 39.07 11.54 355 56649 298561 79388823
Spermatozoa progressive motility decreased 38.44 11.54 9 56995 56 79687328
Accidental exposure to product by child 36.66 11.54 24 56980 2902 79684482
Pancytopenia 36.61 11.54 223 56781 165522 79521862
Sinusitis 35.43 11.54 53 56951 195448 79491936
Seizure 35.39 11.54 50 56954 188784 79498600
Lower respiratory tract infection 34.74 11.54 25 56979 129195 79558189
Cardiogenic shock 34.67 11.54 86 56918 41828 79645556
Musculoskeletal disorder 34.52 11.54 58 56946 21390 79665994
Disseminated intravascular coagulation 34.48 11.54 78 56926 35764 79651620
Leukocytosis 33.69 11.54 87 56917 43368 79644016
Febrile neutropenia 33.44 11.54 72 56932 230927 79456457
Renal failure 33.38 11.54 252 56752 200716 79486668
Echocardiogram abnormal 32.20 11.54 20 56984 2208 79685176
Pleuropericarditis 31.91 11.54 12 56992 432 79686952
Impaired healing 30.85 11.54 12 56992 87643 79599741
Episcleritis 30.61 11.54 15 56989 1040 79686344
Cardiac failure congestive 30.44 11.54 190 56814 142212 79545172
Myocarditis 28.83 11.54 54 56950 21679 79665705
Myalgia 28.73 11.54 229 56775 185412 79501972
Pneumonia 28.61 11.54 318 56686 659928 79027456
Irritable bowel syndrome 28.58 11.54 5 56999 62236 79625148
Stomatitis 28.36 11.54 38 56966 146719 79540665
Confusional state 28.26 11.54 124 56880 317873 79369511
Dizziness 28.08 11.54 241 56763 526200 79161184
Blood creatinine increased 27.78 11.54 198 56806 154859 79532525
Blood pressure systolic increased 27.76 11.54 108 56896 66878 79620506
Anxiety 27.20 11.54 89 56915 248423 79438961
Systemic lupus erythematosus 27.02 11.54 28 56976 121121 79566263
Cholestasis 26.67 11.54 90 56914 52019 79635365
Sedation 26.56 11.54 3 57001 51892 79635492
Leukopenia 26.50 11.54 158 56846 116355 79571029
Enterococcal sepsis 26.22 11.54 19 56985 2707 79684677
Faeces soft 26.13 11.54 31 56973 8292 79679092
Asthma 26.08 11.54 35 56969 135060 79552324
Somnolence 25.19 11.54 87 56917 238894 79448490
Disease progression 24.62 11.54 60 56944 184302 79503082
Folliculitis 24.25 11.54 5 56999 55375 79632009
Musculoskeletal toxicity 23.96 11.54 8 56996 202 79687182
Off label use 23.86 11.54 831 56173 906384 78781000
Hypertrophic osteoarthropathy 23.45 11.54 7 56997 121 79687263
Herbal interaction 23.44 11.54 10 56994 502 79686882
Serum amyloid A protein increased 23.11 11.54 9 56995 357 79687027
Completed suicide 23.10 11.54 273 56731 245494 79441890
Synovitis 22.80 11.54 185 56819 150549 79536835
Arthralgia 22.78 11.54 552 56452 571251 79116133
Hepatic cytolysis 22.76 11.54 56 56948 27095 79660289
Blood cholesterol increased 22.76 11.54 16 56988 83704 79603680
Death 22.53 11.54 278 56726 566236 79121148
Cardiac vein perforation 22.28 11.54 5 56999 25 79687359
Scrotal erythema 22.12 11.54 5 56999 26 79687358
Contraindicated product administered 22.05 11.54 190 56814 157348 79530036
International normalised ratio increased 21.97 11.54 119 56885 84602 79602782
Injection site pain 21.81 11.54 37 56967 129801 79557583
Blood uric acid increased 21.33 11.54 36 56968 13324 79674060
Pericardial drainage 21.25 11.54 9 56995 444 79686940
Heart sounds abnormal 21.06 11.54 13 56991 1420 79685964
Knee arthroplasty 20.92 11.54 3 57001 43245 79644139
Memory impairment 20.52 11.54 30 56974 111704 79575680
Shock 20.36 11.54 73 56931 43475 79643909
Conjunctival haemorrhage 20.35 11.54 23 56981 5842 79681542
Suicidal ideation 20.21 11.54 15 56989 76325 79611059
Depression 20.19 11.54 83 56921 216707 79470677
Ill-defined disorder 20.11 11.54 11 56993 65864 79621520
Drug resistance 19.94 11.54 71 56933 42142 79645242
Hepatocellular injury 19.93 11.54 77 56927 47516 79639868
Myositis 19.89 11.54 43 56961 19125 79668259
Pericarditis 19.78 11.54 135 56869 104101 79583283
Fall 19.48 11.54 239 56765 487390 79199994
Toxic epidermal necrolysis 19.39 11.54 73 56931 44508 79642876
Skin hyperpigmentation 19.38 11.54 25 56979 7278 79680106
Neutrophilia 19.22 11.54 26 56978 7925 79679459
Disease recurrence 19.00 11.54 72 56932 44037 79643347
Agranulocytosis 18.98 11.54 73 56931 44957 79642427
Meningitis gonococcal 18.73 11.54 3 57001 0 79687384
Natural killer cell count 18.55 11.54 4 57000 16 79687368
Renal vasculitis 18.47 11.54 9 56995 616 79686768
Arthritis 18.47 11.54 143 56861 114737 79572647
Amegakaryocytic thrombocytopenia 18.36 11.54 4 57000 17 79687367
Insulin autoimmune syndrome 18.35 11.54 8 56996 424 79686960
Osteomyelitis 17.92 11.54 58 56946 32807 79654577
Aggression 17.89 11.54 7 56997 50951 79636433
Vascular purpura 17.86 11.54 16 56988 3082 79684302
Mixed dementia 17.82 11.54 7 56997 284 79687100
Coma 17.54 11.54 28 56976 100621 79586763
Hypersensitivity vasculitis 17.24 11.54 23 56981 6920 79680464
Autoinflammatory disease 17.09 11.54 7 56997 317 79687067
Cognitive disorder 16.94 11.54 15 56989 69911 79617473
Behcet's syndrome 16.94 11.54 4 57000 26 79687358
Appetite disorder 16.76 11.54 24 56980 7715 79679669
Neoplasm progression 16.71 11.54 8 56996 51674 79635710
Injection site oedema 16.58 11.54 11 56993 1360 79686024
Rebound effect 16.52 11.54 23 56981 7203 79680181
Heart rate abnormal 16.49 11.54 21 56983 6036 79681348
Pulmonary embolism 16.43 11.54 65 56939 171589 79515795
Cytokine release syndrome 16.29 11.54 3 57001 35995 79651389
Pericardial haemorrhage 16.23 11.54 18 56986 4477 79682907
Disturbance in attention 16.22 11.54 8 56996 50793 79636591
Chondrocalcinosis pyrophosphate 16.11 11.54 12 56992 1784 79685600
Pharyngitis streptococcal 15.96 11.54 28 56976 10686 79676698
Hepatic steatosis 15.76 11.54 61 56943 37677 79649707
Migraine 15.57 11.54 24 56980 87469 79599915
Generalised tonic-clonic seizure 15.47 11.54 6 56998 43904 79643480
Ascites 15.17 11.54 19 56985 75543 79611841
Rheumatoid arthritis 15.16 11.54 221 56783 208249 79479135
Exposure during pregnancy 15.06 11.54 31 56973 101101 79586283
Acute respiratory failure 15.01 11.54 83 56921 59458 79627926
Tendinous contracture 14.45 11.54 5 56999 141 79687243
Product use issue 14.31 11.54 220 56784 209602 79477782
Necrotising colitis 14.19 11.54 9 56995 1031 79686353
Penile discomfort 14.12 11.54 3 57001 11 79687373
Cardiac failure 14.10 11.54 171 56833 154671 79532713
Femur fracture 14.09 11.54 5 56999 38647 79648737
Nasopharyngitis 14.06 11.54 115 56889 253766 79433618
Acute generalised exanthematous pustulosis 13.84 11.54 35 56969 17219 79670165
Intentional product use issue 13.69 11.54 59 56945 152053 79535331
Dysarthria 13.58 11.54 17 56987 67605 79619779
Angioedema 13.55 11.54 97 56907 75938 79611446
Sperm concentration decreased 13.52 11.54 4 57000 67 79687317
Tremor 13.52 11.54 69 56935 170014 79517370
Ileal ulcer 13.51 11.54 9 56995 1121 79686263
Disorientation 13.45 11.54 15 56989 62761 79624623
Bone marrow failure 13.39 11.54 72 56932 51035 79636349
Rash maculo-papular 13.36 11.54 77 56927 56001 79631383
Platelet count decreased 13.29 11.54 83 56921 194581 79492803
Enanthema 13.24 11.54 8 56996 841 79686543
HCoV-HKU1 infection 12.91 11.54 3 57001 18 79687366
Blood pressure systolic decreased 12.84 11.54 26 56978 11050 79676334
Thrombocytopenic purpura 12.77 11.54 12 56992 2457 79684927
Deep vein thrombosis 12.74 11.54 44 56960 120875 79566509
Aphasia 12.61 11.54 9 56995 46723 79640661
Palmar-plantar erythrodysaesthesia syndrome 12.57 11.54 4 57000 33130 79654254
Necrotising myositis 12.57 11.54 9 56995 1259 79686125
Strabismus 12.55 11.54 12 56992 2509 79684875
Psychotic disorder 12.51 11.54 7 56997 41395 79645989
Cardio-respiratory arrest 12.47 11.54 38 56966 108472 79578912
Bicytopenia 12.41 11.54 16 56988 4654 79682730
Blood creatine phosphokinase decreased 12.24 11.54 8 56996 965 79686419
Troponin I increased 12.23 11.54 16 56988 4722 79682662
Neutrophil count decreased 12.21 11.54 31 56973 93928 79593456
Intentional self-injury 12.15 11.54 4 57000 32415 79654969
Agitation 12.12 11.54 34 56970 99681 79587703
Osteonecrosis of jaw 12.09 11.54 8 56996 43218 79644166
Acute abdomen 12.09 11.54 13 56991 3124 79684260
White blood cell count decreased 11.98 11.54 82 56922 188206 79499178
Skin disorder 11.91 11.54 52 56952 33891 79653493
Acarodermatitis 11.78 11.54 9 56995 1389 79685995
Abdominal pain 11.76 11.54 363 56641 389206 79298178
Cutaneous vasculitis 11.57 11.54 21 56983 8231 79679153

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M04AC01 MUSCULO-SKELETAL SYSTEM
ANTIGOUT PREPARATIONS
ANTIGOUT PREPARATIONS
Preparations with no effect on uric acid metabolism
FDA CS M0000713 Alkaloids
FDA MoA N0000000239 P-Glycoprotein Interactions
MeSH PA D050256 Antimitotic Agents
MeSH PA D018501 Antirheumatic Agents
MeSH PA D006074 Gout Suppressants
MeSH PA D050257 Tubulin Modulators
FDA MoA N0000182141 Cytochrome P450 3A4 Inhibitors
CHEBI has role CHEBI:25435 mutagens
CHEBI has role CHEBI:35845 gout suppressants
CHEBI has role CHEBI:67079 anti-inflammatory agents
FDA EPC N0000193949 Alkaloid

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Familial Mediterranean fever indication 12579009 DOID:2987
Atherosclerosis indication 38716007 DOID:1936
Cardiovascular disease indication 49601007 DOID:1287
Chronic gouty arthritis indication 68451005
Gout indication 90560007 DOID:13189
Gout Prevention indication
Peptic ulcer contraindication 13200003 DOID:750
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diarrhea contraindication 62315008
Leukopenia contraindication 84828003 DOID:615
Anemia due to enzyme deficiency contraindication 111577008
Disorder of muscle contraindication 129565002 DOID:423
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Impaired renal function disorder contraindication 197663003
Rhabdomyolysis contraindication 240131006
Renal dialysis contraindication 265764009
Uric acid renal calculus contraindication 274401005
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Aplastic anemia contraindication 306058006 DOID:12449
Bone marrow depression contraindication 307762000
Granulocytopenic disorder contraindication 417672002
Vomiting contraindication 422400008
Uric Acid Nephropathy Gout contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.19 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7964647 Oct. 6, 2028 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7964648 Oct. 6, 2028 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7981938 Oct. 6, 2028 A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8093296 Oct. 6, 2028 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8093297 Oct. 6, 2028 FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8093298 Oct. 6, 2028 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8097655 Oct. 6, 2028 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8415395 Oct. 6, 2028 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8415396 Oct. 6, 2028 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7619004 Dec. 3, 2028 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7935731 Dec. 3, 2028 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7601758 Feb. 10, 2029 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7820681 Feb. 17, 2029 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7906519 Feb. 17, 2029 METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 7915269 Feb. 17, 2029 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8440721 Feb. 17, 2029 METHOD OF TREATING GOUT FLARES
0.6MG COLCRYS TAKEDA PHARMS USA N022352 July 29, 2009 RX TABLET ORAL 8440722 Feb. 17, 2029 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 8927607 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 9399036 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 9555029 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 9675613 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.6MG MITIGARE HIKMA INTL PHARMS N204820 Sept. 26, 2014 RX CAPSULE ORAL 9789108 Aug. 22, 2033 METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES
0.5MG LODOCO AGEPHA PHARMA FZ N215727 June 16, 2023 RX TABLET ORAL 10130585 Dec. 31, 2034 A METHOD OF TREATING CARDIOVASCULAR DISEASE
0.5MG LODOCO AGEPHA PHARMA FZ N215727 June 16, 2023 RX TABLET ORAL 10206891 Jan. 22, 2035 A METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT; ACUTE CORONARY SYNDROME, OUT-OF-HOSPITAL CARDIAC ARREST, AND/OR NONCARDIOEMBOLIC ISCHEMIC STROKE
0.5MG LODOCO AGEPHA PHARMA FZ N215727 June 16, 2023 RX TABLET ORAL 10265281 Jan. 22, 2035 A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT
0.5MG LODOCO AGEPHA PHARMA FZ N215727 June 16, 2023 RX TABLET ORAL 10842762 Jan. 22, 2035 A METHOD OF TREATING AND/OR REDUCING THE RISK OF INFLAMMATION, ATHEROSCLEROTIC VASCULAR DISEASE, AND CHOLESTEROL CRYSTAL INDUCED INFLAMMATION WITHIN ATHEROSCLEROTIC PLAQUES
0.5MG LODOCO AGEPHA PHARMA FZ N215727 June 16, 2023 RX TABLET ORAL 11026899 Jan. 22, 2035 A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT
0.5MG LODOCO AGEPHA PHARMA FZ N215727 June 16, 2023 RX TABLET ORAL 11026900 Jan. 22, 2035 A METHOD FOR TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT
0.5MG LODOCO AGEPHA PHARMA FZ N215727 June 16, 2023 RX TABLET ORAL 11026901 Jan. 22, 2035 A METHOD FOR TREATING AND/OR REDUCING THE RISK OF ACUTE MYOCARDIAL INFARCTION
0.5MG LODOCO AGEPHA PHARMA FZ N215727 June 16, 2023 RX TABLET ORAL 9744144 Jan. 22, 2035 METHOD OF TREATING AND/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT
0.6MG/5ML GLOPERBA SCILEX PHARMS N210942 Jan. 30, 2019 RX SOLUTION ORAL 10383820 Nov. 22, 2036 A METHOD OF PROPHYLACTIC TREATMENT OF GOUT FLARES IN ADULTS COMPRISES ADMINISTERING TO A PATIENT A LIQUID COLCHICINE ORAL SOLUTION

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Cytochrome P450 3A4 Enzyme Ki 4.19 WOMBAT-PK
Multidrug resistance protein 1 Transporter Kd 3.80 WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK
Glycine receptor subunit alpha-1 Ion channel IC50 3.49 WOMBAT-PK
Glycine receptor subunit alpha-2 Ion channel IC50 4.19 WOMBAT-PK
Tubulin beta chain Structural INHIBITOR Ki 5.24 WOMBAT-PK
Serine/threonine-protein kinase pim-1 Kinase IC50 5.37 CHEMBL
Bromodomain-containing protein 4 Unclassified INHIBITOR Kd 4.70 IUPHAR
Tubulin beta-4B chain Structural Ki 5.24 WOMBAT-PK
Tubulin alpha-1A chain Structural Ki 5.60 CHEMBL
Tubulin beta-2B chain Structural Ki 6.11 CHEMBL
Tubulin polymerization-promoting protein Unclassified EC50 6.12 CHEMBL
Tubulin Structural IC50 6.10 CHEMBL
Tubulin Structural Ki 5.24 CHEMBL

External reference:

IDSource
4020930 VUID
N0000148412 NUI
D00570 KEGG_DRUG
2683 RXNORM
4017416 VANDF
4020930 VANDF
C0009262 UMLSCUI
CHEBI:27882 CHEBI
LOC PDB_CHEM_ID
CHEMBL107 ChEMBL_ID
D003078 MESH_DESCRIPTOR_UI
DB01394 DRUGBANK_ID
6167 PUBCHEM_CID
2367 IUPHAR_LIGAND_ID
SML2Y3J35T UNII
4493 MMSL
581 MMSL
d00150 MMSL
002372 NDDF
387413002 SNOMEDCT_US
73133000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0143-3018 CAPSULE 0.60 mg ORAL NDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0143-3018 CAPSULE 0.60 mg ORAL NDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0254-2008 TABLET, FILM COATED 0.60 mg ORAL NDA AUTHORIZED GENERIC 32 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0378-1086 TABLET, FILM COATED 0.60 mg ORAL ANDA 28 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0378-1086 TABLET, FILM COATED 0.60 mg ORAL ANDA 28 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0591-2562 TABLET, FILM COATED 0.60 mg ORAL ANDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0591-2562 TABLET, FILM COATED 0.60 mg ORAL ANDA 27 sections
Probenecid and Colchicine HUMAN PRESCRIPTION DRUG LABEL 2 0591-5325 TABLET 0.50 mg ORAL ANDA 13 sections
Probenecid and Colchicine HUMAN PRESCRIPTION DRUG LABEL 2 0591-5325 TABLET 0.50 mg ORAL ANDA 13 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0904-6732 CAPSULE 0.60 mg ORAL NDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7120 TABLET, FILM COATED 0.60 mg ORAL ANDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 0904-7120 TABLET, FILM COATED 0.60 mg ORAL ANDA 27 sections
Colcrys HUMAN PRESCRIPTION DRUG LABEL 1 13310-119 TABLET, FILM COATED 0.60 mg ORAL NDA 29 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 23155-855 TABLET, FILM COATED 0.60 mg ORAL ANDA 23 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 31722-899 TABLET, FILM COATED 0.60 mg ORAL ANDA 26 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 42292-054 TABLET, FILM COATED 0.60 mg ORAL ANDA 28 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 42292-054 TABLET, FILM COATED 0.60 mg ORAL ANDA 28 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 42292-054 TABLET, FILM COATED 0.60 mg ORAL ANDA 28 sections
Colcrys HUMAN PRESCRIPTION DRUG LABEL 1 43353-854 TABLET, FILM COATED 0.60 mg ORAL NDA 28 sections
colchicine HUMAN PRESCRIPTION DRUG LABEL 1 43598-372 TABLET 0.60 mg ORAL ANDA 28 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 49884-171 TABLET, FILM COATED 0.60 mg ORAL ANDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3465 CAPSULE 0.60 mg ORAL NDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 50090-3465 CAPSULE 0.60 mg ORAL NDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 50268-187 TABLET 0.60 mg ORAL ANDA 19 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 50268-187 TABLET 0.60 mg ORAL ANDA 19 sections
Probenecid and Colchicine Human Prescription Drug Label 2 50742-263 TABLET 0.50 mg ORAL ANDA 13 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 51407-082 TABLET, FILM COATED 0.60 mg ORAL ANDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 51407-082 TABLET, FILM COATED 0.60 mg ORAL ANDA 27 sections
Colchicine HUMAN PRESCRIPTION DRUG LABEL 1 51407-082 TABLET, FILM COATED 0.60 mg ORAL ANDA 27 sections
Colcrys HUMAN PRESCRIPTION DRUG LABEL 1 54868-6256 TABLET, FILM COATED 0.60 mg ORAL NDA 29 sections